Search
Friday 31 July 2015
  • :
  • :

Pre-Market News Buzz on: Adobe Systems (NASDAQ:ADBE), Flotek Industries (NYSE:FTK), Emerson Electric (NYSE:EMR), Novavax, (NASDAQ:NVAX)

On Friday, Adobe Systems Incorporated (NASDAQ:ADBE)’s shares inclined 0.42% to $80.98.

Tata Consultancy Services, a leading IT services, consulting and business solutions organization, has been selected by Adobe (ADBE), a global leader in digital marketing and digital media solutions, as a Premier Partner, the highest level of partnership among Adobe’s global ecosystem. This new partnership enables TCS clients to fully leverage Adobe’s Marketing Platform and its core solutions, allowing them to design and execute customized strategies and integrated marketing campaigns to suit specific target audiences and customer profiles.

TCS’ strengths in digital marketing solutions and services, advanced technology knowledge, trusted domain expertise, and vast implementation and integration experience, combined with Adobe’s leadership in its Digital Marketing Platform and core solutions, provides customers with an industry-leading, best-in-class, complete end-to-end integrated marketing solution.

As enterprises increasingly preceding digital technologies into their core marketing strategies, they can be assured that TCS and Adobe’s Digital Marketing Solutions and Services will harness centralized and shared data to comprising deliver contextually relevant, real-time personalized experiences to consumers. In turn, these will drive loyalty, improve customer experience and enhance customer satisfaction. Ultimately, this allows enterprise clients to manage complex digital marketing requirements, drive customer acquisition, strengthen retention programs, enhance marketing ROI, build stronger customer relationships, and enhance brand value and market share.

Adobe Systems Incorporated is a diversified software company worldwide. It operates in three segments: Digital Media, Digital Marketing, and Print and Publishing. The Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content. This segment’s flagship product is Creative Cloud, a subscription service that allows customers to download and install the latest versions of its creative products.

Flotek Industries Inc (NYSE:FTK)’s shares dropped -5.27% to $16.71.

Flotek Industries, Inc. (FTK) declared results for the three months ended June 30, 2015.

As stated on Form 10-Q filed with the U.S. Securities and Exchange Commission, Flotek stated that revenue for the three months ended June 30, 2015, was $87.0 million contrast to $105.3 million for the three months ended June 30, 2014 and $82.4 million for the first quarter of 2015. Second quarter, 2015 revenue raised 5.6% sequentially but reduced 17.4% when contrast to the same period in 2014. The decrease in year-over-year revenue was driven by the steep decline in oilfield activity; however, the enhance in sequential revenue was driven almost entirely by raised sales of Flotek’s Complex nano-Fluid® completion chemistries as the Company’s marketing campaign and new direct distribution model offered noteworthyrevenue opportunities during the quarter.

For the three months ended June 30, 2015, the Company stated net income (not taking into account non-cash charges) of $1.1 million, or $0.02 per common share (fully diluted), contrast to net income of $11.0 million, or $0.20 per common share (fully diluted) for the same period in 2014 and a net loss of $1.5 million or $0.03 per common share (fully diluted) in the first quarter of this year.

During the second quarter, as a result of reduced rig activity and Flotek’s expectations for future market activity, the Company refocused its Drilling Technologies segment to concentrate on products and markets that leadership believes have the best opportunity for profitable growth in the future. As a result, the Company recorded a pre-tax impairment charge of $20.4 million in the second quarter of 2015.

Flotek Industries, Inc. develops and supplies oilfield products, services, and equipment to the oil, gas, and mining industries in the United States and internationally. Its Energy Chemical Technologies segment designs, develops, manufactures, packages, and markets specialty chemicals used in oil and gas well drilling, cementing, completion, stimulation, and production. This segment also constructs and manages automated material handling facilities; and manages loading facilities and blending operations for oilfield services companies.

At the end of Friday’s trade, Emerson Electric Co. (NYSE:EMR)‘s shares dipped -1.60% to $50.69.

Emerson (EMR) and WeatherBug® are partnering to leverage big weather data and the Internet of Things to assist consumers stay comfortable, save money and conserve energy – no matter the weather. Consumers in Texas using the Sensi™ Wi-Fi Programmable Thermostat from Emerson can now take advantage of WeatherBug Home – a software upgrade that optimizes connected thermostats based on the latest weather conditions – at no additional cost.

On average, the weather influences about 50 percent of a home’s energy use. By integrating WeatherBug Home’s real-time, hyper-local data and patent-pending algorithms, consumers can have their Emerson Sensi Thermostats optimized for the weather to maximize their comfort and savings. While WeatherBug Home saves consumers money – an average of $75 each year – it also assists local energy utilities boost efficiency and stability, better allocate resources, and keep the power on during peak demand times.

Emerson Electric Co. provides technology and engineering solutions to industrial, commercial, and consumer markets worldwide. It operates through five segments: Process Administration, Industrial Automation, Network Power, Climate Technologies, and Commercial & Residential Solutions. The Process Administration segment offers products and technology, and engineering, project administration, and consulting services for precision measurement, control, monitoring, asset optimization, and safety and reliability of oil and gas reservoirs and plants.

Novavax, Inc. (NASDAQ:NVAX), ended its Friday’s trading session with -1.67% loss, and closed at $11.79.

Novavax, Inc. (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared the appointment of Gail K. Boudreaux to its Board of Directors.

Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience comprises more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is presently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline comprises respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, in addition to pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, in addition to rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *